- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04475315
Ventricular Sling for Heart Failure With Reduced Ejection Fraction
Left Ventricular Papillary Muscle Sling for Heart Failure With Reduced Ejection Fraction (Papillary Muscle Sling)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Sling is used to draw together the ventricular walls at the base of the papillary muscles. This technique has previously been used in conjunction with mitral valve surgery, and has shown significant benefits for the patients.
The reduction in the lateral inter-papillary muscle separation and in the left ventricular volume provided by this technique is expected to improve ventricular function, limit progression of ventricular dilation, and avoid progression of MR when performed without mitral valve surgery in patients with symptomatic ventricular dilation.
Study Type
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients with symptomatic heart failure with reduced ejection fraction and either ischemic or non-ischemic cardiomyopathies, referred for CABG surgery. Suitability for the ventricular sling procedure is determined by the surgeon and or cardiologist, using some or all the criteria described below:
- Left ventricular end diastolic diameter is greater than or equal to 55mm.
- Ejection fraction ≥20% and ≤40%
- FMR grade ≤ 2+ (≤ mild FMR) as defined by the guidelines of the American society of echocardiography at the time of the study approval (via a transthoracic or transesophageal echo).
- End-systolic Interpapillary muscle distance ≥ 20mm
- Cardiomyopathy of ischemic or non-ischemic origins.
- Able to sign informed consent and release of medical information forms, or able to assign a legal representative who can sign on the patient's behalf.
Exclusion Criteria:
- Any evidence of structural (chordal or leaflet) mitral lesions.
- Planned concomitant intra-operative procedures (except for closure of patent foramen ovale or atrial septal defect or coronary revascularization)
- Planned concomitant intra-operative Maze procedure for symptomatic paroxysmal atrial fibrillation.
- Persistent atrial fibrillation
- Prior mitral valve repair
- Contraindication for cardiopulmonary bypass
- Clinical signs of cardiogenic shock
- ST segment elevation myocardial infarction within 14 days prior to inclusion in this study.
- Congenital heart disease (except PFO or ASD)
- Chronic renal insufficiency defined by Creatinine ≥ 3.0 or chronic renal replacement therapy, who are contraindicated for cardiac surgery
- Recent history of psychiatric disease that is likely to impair compliance with the study protocol, in the judgement of the investigator
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Papillary Muscle Sling Group
Participants in the papillary muscle sling group will receive the sling technique performed in conjunction with their standard of care (SOC) Coronary Artery Bypass Grafting (CABG) surgery.
|
The sling is made of a Gore-Tex sheet or by using a 4 mm Gore-Tex vascular graft implanted around the base of the papillary muscles and tightened.
Standard of care Coronary Artery Bypass Grafting (CABG) surgery will be performed to improve blood flow to the heart by bypassing the narrowed segment of a severely diseased coronary artery
|
Active Comparator: Controls Group
Participants in the control group will receive their SOC CABG surgery only, without any additional intervention.
|
Standard of care Coronary Artery Bypass Grafting (CABG) surgery will be performed to improve blood flow to the heart by bypassing the narrowed segment of a severely diseased coronary artery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in left ventricular function as assessed by LVEF
Time Frame: Baseline, up to 5 years
|
Change in Left Ventricular Ejection Fraction (LVEF) will be reported as a change in percent ejection fraction assessed via echocardiogram
|
Baseline, up to 5 years
|
Change in left ventricular volume
Time Frame: Baseline, up to 5 years
|
End systolic and end diastolic left ventricular volumes will both be evaluated in mL using echocardiogram.
|
Baseline, up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality Rate
Time Frame: 5 years
|
Rate of reported mortality rate will be evaluated.
|
5 years
|
Number of Major Adverse Cardiac Events (MACE)
Time Frame: 5 years
|
MACE is defined as a composite of clinical events comprised of death, stroke, worsening heart failure defined as +1 New York Heart Association (NYHA) class, Congestive Heart Failure (CHF) hospitalization and mitral valve intervention as evaluated by treating physician
|
5 years
|
Percentage of participants at each FMR severity grade
Time Frame: Baseline, up to 5 years
|
Functional Mitral Regurgitation (FMR) severity is graded on a scale of 1 to 4 with 1 = none, 2 =mild, 3 = moderate and 4 =severe.
This outcome will report the percentage of participants with reported none, mild, moderate or severe mitral regurgitation as assessed via echocardiogram by treating physician.
|
Baseline, up to 5 years
|
Change in MLHF Questionnaire Score
Time Frame: Baseline, up to 5 years
|
Minnesota Living with Heart Failure (MLHF) is a 21-item questionnaire with a total score ranging from 0 (indicating heart failure has no affect to life) to 105 (indicating the greatest affect to life).
|
Baseline, up to 5 years
|
Change in Functional Status as assessed by 6MWT
Time Frame: Baseline, up to 5 years
|
Functional status will be assessed as the distance reached in meters via the 6-minute Walk Test (6MWT).
|
Baseline, up to 5 years
|
All Cause Readmission Rate
Time Frame: 5 years
|
All cause readmission rate will be calculated for any case throughout the duration of study participation.
|
5 years
|
Heart Failure Readmission Rate
Time Frame: 5 years
|
Heart failure readmission rate will be calculated for heart failure throughout the duration of study participation.
|
5 years
|
Incidence of Mitral Leaflet Tenting
Time Frame: 5 years
|
Mitral Leaflet tenting will be evaluated using echocardiographic imaging.
|
5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Joseph Lamelas, MD, University of Miami
Publications and helpful links
General Publications
- Lamelas J, Mihos C, Santana O. Surgical technique: papillary muscle sling for functional mitral regurgitation during minimally invasive valve surgery. Heart Surg Forum. 2013 Oct;16(5):E295-7. doi: 10.1532/hsf98.2013209.
- Santana O, Solenkova NV, Pineda AM, Mihos CG, Lamelas J. Minimally invasive papillary muscle sling placement during mitral valve repair in patients with functional mitral regurgitation. J Thorac Cardiovasc Surg. 2014 Jan;147(1):496-9. doi: 10.1016/j.jtcvs.2013.03.006. Epub 2013 Mar 29.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20200679
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
US Department of Veterans AffairsCompleted
Clinical Trials on Papillary Muscle Sling
-
Emory UniversityNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...CompletedCardiovascular Diseases | Coronary Artery Disease | Heart Disease | Valvular Heart Disease | Congestive Heart Failure | Cardiomyopathy | Mitral Valve DiseaseUnited States
-
The Federal Centre of Cardiovascular Surgery, RussiaUnknown
-
Christiana Care Health ServicesTerminated
-
National Taiwan University HospitalUnknown
-
University Hospital Inselspital, BerneCompletedSurgery | Cholecystolithiasis | CholedocholithiasisSwitzerland
-
University of Southern CaliforniaRecruiting
-
Assistance Publique - Hôpitaux de ParisCompletedAutoimmune Diseases | Gingivitis | Gingival Diseases | Oral Lichen Planus
-
American Medical SystemsCompletedUrinary Incontinence, StressCanada, United States
-
University of AlbertaCompleted
-
Venizelio General HospitalCompletedEndoscopic Papillary Balloon Dilation | Bile Duct Stones | Endoscopic Sphincterotomy | Stone RecurrenceGreece